| 摘要 |
Nucleoside analogues such as ribofuranosyl-(beta)-D-pyrrolopyrimidine compounds and ribofuranosyl pyrrolopyrimidine N-oxide compounds and pharmaceutically acceptable salts and mixtures thereof. Compositions comprising these compounds and pharmaceutically acceptable carriers have also been disclosed. The invention further includes ribofuranosyl compounds having the anomeric position substituted with substituents selected from the group consisting of: -O-(C1-C18)alkyl, -O-(C1-C18)acyl, halogen, O-tosyl, or -OSO2R11, wherein R11 is -(C1-C18)alkyl or -(C6-C24)aryl. Methods of preparing said compounds have also been disclosed. Methods of treating a disease or condition such as inflammation, certain heart conditions, gastric ulcers, osteoarthritis, neutrophil function, or promoting vasodilation, among others comprise administering to a subject in need of the treatment an adenosine kinase activity inhibitory effective amount of claimed compounds or compositions thereof. |
